Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880620 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
A Phase 3 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 381
- Enrollment target
NCT00880620 is a Phase 3 study that has completed, run by Impax Laboratories. The registered enrollment target is 381 participants.
The verdict
NCT00880620, a Phase 3 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 381 participants
- Enrollment target
Study Summary
This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.
Interventions
- DRUG Placebo
- DRUG IPX066 95 mg LD
- DRUG IPX066 145 mg LD
- DRUG IPX066 195 mg LD
- DRUG IPX066 245 mg LD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 381 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00880620
The ClinicalTrials.gov registry entry for NCT00880620 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 381 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00880620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00880620 about?
NCT00880620 is a clinical study titled "A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease". This study examines the efficacy of three doses of IPX066 as compared to placebo in Parkinson's disease.
What is the current status of trial NCT00880620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 381 participants. The study started on 2009-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00880620?
The interventions under investigation include: Placebo (DRUG), IPX066 95 mg LD (DRUG), IPX066 145 mg LD (DRUG), IPX066 195 mg LD (DRUG), IPX066 245 mg LD (DRUG).
Who is sponsoring clinical trial NCT00880620?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.